Home
Morepen Laboratories Ltd Share Price History
Morepen Laboratories Ltd
NSE : 05 Feb, 2025
66.162.0 (3.2%)
Prev Close
64.1
Open Price
64.3
Bid Price (QTY)
-
Offer Price (QTY)
-
Volume
2549360
Today's High / Low
66.5 / 64.3
52 WK High / Low
100.9 / 38.5
Market Price of Morepen Laboratories Ltd
1M
1Y
3Y
5Y
Monitoring Morepen Laboratories Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.
History Market Price
| Date | Price | Open | High | Low |
|---|
Returns Comparison
1W
1M
3M
6M
1Y
3Y
5Y
10Y
Growth Parameters
| Parameter |  2017 |
|---|---|
| Sales (Cr.) | NaN |
| Sales YoY Gr. | - |
| Adj EPS | 0.53 |
| YoY Gr. | - |
| Net Profit (Cr.) | 24 |
| BVPS | 4.36 |
Key Financial Parameters
| Parameter | 2015 |
|---|---|
| Return on Capital Emp. % | 2.33 |
| Op. Profit Mgn % | 12.15 |
| Net Profit Mgn % | 0.52 |
| Debt to Equity % | 0.29 |
Latest Shareholding
Promoters Holdings Over Time
About Morepen Laboratories Ltd
- Morepen Laboratories Limited is an India-based pharmaceutical company.
- Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
- The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
- It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
- The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.
FAQs for Morepen Laboratories Ltd Share Price History
What are the key events that typically impact Morepen Laboratories Ltd's share price history?
Key events that impact Morepen Laboratories Ltd’s share price history include quarterly earnings releases, product launches, leadership changes, economic policies, and geopolitical developments.
How do stock splits affect Morepen Laboratories Ltd's share price history?
Stock splits reduce the nominal price of Morepen Laboratories Ltd's shares by increasing the number of outstanding shares, which typically makes the stock more accessible to a broader range of investors. Although the total market value of the company remains unchanged after the split, the split can affect investor perception and liquidity, potentially influencing the share price in the longer term.
How do dividends impact the share price history of Morepen Laboratories Ltd?
Dividends can influence Morepen Laboratories Ltd's share price history by typically causing a temporary dip on the ex-dividend date, as the stock price often adjusts to reflect the dividend payout. Over time, the impact of dividends on the share price may be offset by the company's overall financial performance and market conditions.
How do corporate announcements affect Morepen Laboratories Ltd’s share price history?
Corporate announcements such as mergers, acquisitions, or strategic shifts can lead to significant price changes. Any optimistic development news on Morepen Laboratories Ltd generally boosts the company’s share price, whereas negative news can lead to a decline in share price.
How can I use technical analysis to understand Morepen Laboratories Ltd’s share price history?
To understand Morepen Laboratories Ltd’s share price history using technical analysis, examine charts for patterns such as trends, support, and resistance levels, and apply indicators like moving averages or Relative Strength Index (RSI) to gauge potential future movements. Analyze historical data to identify recurring trends and signals that might suggest how the share price could behave under similar conditions.
Popular Search
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
